CoreTissue BioEngineering Initiates Randomized ACL Reconstruction Trial
YOKOHAMA, Japan, May 7, 2026 CoreTissue BioEngineering announced the initiation of the randomized controlled cohort in its ongoing clinical...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
YOKOHAMA, Japan, May 7, 2026 CoreTissue BioEngineering announced the initiation of the randomized controlled cohort in its ongoing clinical...
UNITED STATES | January 27, 2026 — ABANZA, a medical technology company focused on advancing soft-tissue fixation solutions, announced...
